Comments Subscribe to Personal Liberty News Feed Subscribe to Personal Liberty
 

Drug Company To Pay $3 Billion Settlement For Bogus Marketing

November 7, 2011 by  

Drug Company To Pay $3 Billion Settlement For Bogus Marketing

A U.K. drug company has agreed to pay $3 billion to end U.S. criminal and civil investigations into whether it marketed drugs for unapproved uses and other matters.

The company, GlaxoSmithKline PLC, was being probed  for its sales and marketing practices for drugs including the antidepressants Paxil and Wellbutrin, according to The Associated Press. The company was also facing questions about its development and marketing of a diabetes drug called Avandia, which has been withdrawn from the European market and limited in the United States because of increased heart attack risks.

An investigation was begun by the U.S. Attorney’s office of Colorado in 2004 and later taken over by the U.S. Attorney’s Office of Massachusetts into whether the company was promoting drugs for unapproved uses, and influencing doctors to prescribe them.

The Justice Department also launched investigations into possible inappropriate use of the nominal price exception under the Medicaid Rebate Program, according to The Washington Post.

The $3 billion settlement, which Glaxo says will be paid with its “cash resources,” will be the largest pharmaceutical marketing settlement in U.S. history.

Sam Rolley

Staff writer Sam Rolley began a career in journalism working for a small town newspaper while seeking a B.A. in English. After learning about many of the biases present in most modern newsrooms, Rolley became determined to find a position in journalism that would allow him to combat the unsavory image that the news industry has gained. He is dedicated to seeking the truth and exposing the lies disseminated by the mainstream media at the behest of their corporate masters, special interest groups and information gatekeepers.

Facebook Conversations

Join the Discussion:
View Comments to “Drug Company To Pay $3 Billion Settlement For Bogus Marketing”

Comment Policy: We encourage an open discussion with a wide range of viewpoints, even extreme ones, but we will not tolerate racism, profanity or slanderous comments toward the author(s) or comment participants. Make your case passionately, but civilly. Please don't stoop to name calling. We use filters for spam protection. If your comment does not appear, it is likely because it violates the above policy or contains links or language typical of spam. We reserve the right to remove comments at our discretion.

Is there news related to personal liberty happening in your area? Contact us at newstips@personalliberty.com

Bottom
close[X]

Sign Up For Personal Liberty Digest™!

PL Badge

Welcome to PersonalLiberty.com,
America's #1 Source for Libertarian News!

To join our group of freedom-loving individuals and to get alerts as well as late-breaking conservative news from Personal Liberty Digest™...

Privacy PolicyYou can opt out at any time. We protect your information like a mother hen. We will not sell or rent your email address to anyone for any reason.